Literature DB >> 29196241

Scleroderma skin ulcers definition, classification and treatment strategies our experience and review of the literature.

Dilia Giuggioli1, Andreina Manfredi1, Federica Lumetti1, Michele Colaci1, Clodoveo Ferri2.   

Abstract

BACKGROUND: Skin ulcers (SU) are one of the most frequent manifestations of systemic sclerosis (SSc). SSc-SU are very painful, often persistent and recurrent; they may lead to marked impairment of patient's activities and quality of life. Despite their severe impact on the whole SSc patient's management, the proposed definition, classification criteria, and therapeutic strategies of SSc-SU are still controversial.
OBJECTIVE: The present study aimed to elaborate a comprehensive proposal of definition, classification, and therapeutic strategy of SSc-SU on the basis of our long-term single center experience along with a careful revision of the world literature on the same topic.
METHODS: A series of 282 SSc patients (254 females and 28 males; 84% with limited and 16% diffuse cutaneous SSc; mean age of 51.5±13.9SD at SSc onset; mean follow-up 5.8±4.6SDyears) enrolled during the last decade at our Rheumatology Unit were retrospectively evaluated with specific attention to SSc-SU. The SSc-SU were classified in 5 subtypes according to prominent pathogenetic mechanism(s) and localization, namely 1. digital ulcers (DU) of the hands or feet, 2. SU on bony prominence, 3. SU on calcinosis, 4. SU of lower limbs, and 5. DU presenting with gangrene. This latter is a very harmful evolution of both DU of the hands and feet needing a differential diagnosis with critical limb ischemia.
RESULTS: During the follow up period, one or more episodes of SSc-SU were recorded in over half patients (156/282, 55%); skin lesions were often recurrent and difficult-to-heal because of local complications, mainly infections (67.3%), in some cases associated to osteomyelitis (19.2%), gangrene (16%), and/or amputation (11.5%). SSc-SU were significantly associated with lower patients' mean age at the disease onset (p=0.024), male gender (p=0.03), diffuse cutaneous subset (p=0.015), calcinosis (p=0.002), telangiectasia (p=0.008), melanodermia (p<0.001), abnormal PAPs (p=0.036), and/or altered inflammation reactant (CRP, p=0.001). Therapeutic strategy of SSc-SU included both systemic and local pharmacological treatments with particular attention to complicating infections and chronic/procedural pain, as well as a number of non-pharmacological measures. Integrated local treatments were often decisive for the SSc-SU healing; they were mainly based on the wound bed preparation principles that are summarized in the acronym TIME (necrotic Tissue, Infection/Inflammation, Moisture balance, and Epithelization). The updated review of the literature focusing on this challenging issue was analyzed in comparison with our experience.
CONCLUSIONS: The recent advancement of knowledge and management strategies of SSc-SU achieved during the last years lead to the clear-cut improvement of patients' quality of life and reduced long-term disability.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Classification; Debridement; Definition; Digital ulcers; Procedural pain; Scleroderma; Skin ulcers; Systemic sclerosis; TIME; Wound bed preparation

Mesh:

Year:  2017        PMID: 29196241     DOI: 10.1016/j.autrev.2017.11.020

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  14 in total

Review 1.  Management of Raynaud's phenomenon in systemic sclerosis-a practical approach.

Authors:  Andreu Fernández-Codina; Esperanza Cañas-Ruano; Janet E Pope
Journal:  J Scleroderma Relat Disord       Date:  2019-01-28

2.  The impact of skin calcinosis on digital ulcers in patients with SSc: clinical and prognostic stratification using the "wound bed score".

Authors:  Simone Barsotti; Valentina Venturini; Marco Di Battista; Agata Janowska; Valentina Dini; Alessandra Della Rossa; Marta Mosca
Journal:  Int Wound J       Date:  2020-09-14       Impact factor: 3.315

3.  Inpatient Management of Mucocutaneous GVHD.

Authors:  Toral Vaidya; Christian Menzer; Doris M Ponce; Alina Markova
Journal:  Curr Dermatol Rep       Date:  2019-11-11

4.  Trends in Demographics, Hospitalization Outcomes, Comorbidities, and Mortality Risk among Systemic Sclerosis Patients.

Authors:  Oluyemisi Amoda; Virendrasinh Ravat; Sorabh Datta; Bipin Saroha; Rikinkumar S Patel
Journal:  Cureus       Date:  2018-05-14

5.  Skin thickness score as a surrogate marker of organ involvements in systemic sclerosis: a retrospective observational study.

Authors:  Kazuki M Matsuda; Ayumi Yoshizaki; Ai Kuzumi; Takemichi Fukasawa; Satoshi Ebata; Shunsuke Miura; Tetsuo Toyama; Asako Yoshizaki; Hayakazu Sumida; Yoshihide Asano; Koji Oba; Shinichi Sato
Journal:  Arthritis Res Ther       Date:  2019-05-28       Impact factor: 5.156

Review 6.  Exosomes in Systemic Sclerosis: Messengers Between Immune, Vascular and Fibrotic Components?

Authors:  Marta Colletti; Angela Galardi; Maria De Santis; Giacomo Maria Guidelli; Angela Di Giannatale; Luigi Di Luigi; Cristina Antinozzi
Journal:  Int J Mol Sci       Date:  2019-09-04       Impact factor: 5.923

7.  Use of Neem oil and Hypericum perforatum for treatment of calcinosis-related skin ulcers in systemic sclerosis.

Authors:  Dilia Giuggioli; Federica Lumetti; Amelia Spinella; Emanuele Cocchiara; Gianluca Sighinolfi; Giorgia Citriniti; Michele Colaci; Carlo Salvarani; Clodoveo Ferri
Journal:  J Int Med Res       Date:  2019-12-25       Impact factor: 1.671

8.  CD21low B cells are predictive markers of new digital ulcers in systemic sclerosis.

Authors:  Marcella Visentini; Chiara Pellicano; Giorgia Leodori; Ramona Marrapodi; Stefania Colantuono; Antonietta Gigante; Milvia Casato; Edoardo Rosato
Journal:  Clin Exp Immunol       Date:  2021-06-06       Impact factor: 4.330

Review 9.  Management of systemic sclerosis: the first five years.

Authors:  David Roofeh; Dinesh Khanna
Journal:  Curr Opin Rheumatol       Date:  2020-05       Impact factor: 4.941

Review 10.  Active roles of dysfunctional vascular endothelium in fibrosis and cancer.

Authors:  Tien Hsu; Hieu-Huy Nguyen-Tran; Maria Trojanowska
Journal:  J Biomed Sci       Date:  2019-10-28       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.